Sie suchten nach: erysipelas (Englisch - Maltesisch)

erysipelas
irsipla

wound infection, erysipelas,
infezzjoni fil-ferita, erisipelas,

swine erysipelas vaccine (inactivated)
vaċċin ta’ erysipelas tal-majjali (inattivat)

this will help protect them against swine erysipelas.
dan se jgħin jipproteġihom kontra erysipelas tal-majjali.

for swine erysipelas two laboratory studies were conducted.
għal erysipelas tal-majjali twettqu żewġ studji f’laboratorju.

porcine parvovirosis and swine erysipelas vaccine (inactivated)
parvovirus tal-majjali u vaċċin erysipelas tal-majjali (inattivati)

this will help protect them against porcine parvovirus and swine erysipelas.
dan se jgħin jipproteġihom kontra parvovirus tal-majjali u erysipelas tal-majjali.

to stimulate active immunisation against porcine parvovirus and swine erysipelas.
biex jistimula l-immunizzazzjoni attiva kontra l-parvovirus tal-majjali u l-erisipelas tal-majjali.

however, the duration of immunity of the erysipelas component following mixed use has not been investigated.
madankollu, it-tul tal-immunità tal-komponent tal-erysipelas wara l-użu mħallat għadu ma ġiex investigat.

helicobacter infection, herpes zoster, erysipelas, wound infection, gingival infection, labrynthitis, bacterial infection
infezzjoni tal-helicobacter, herpes zoster, irsipla, infezzjoni fil-ferita, infezzjoni fil-ħniek, labirintite

eryseng is used to protect male and female pigs against swine erysipelas caused by erysipelothrix rhusiopathiae bacteria of specific types called serotype 1 and serotype 2.
eryseng jintuża biex jipproteġi majjali rġiel u nisa kontra erysipelas tal-majjali kkawżata mill-batterji erysipelothrix rhusiopathiae ta’ tipi speċifiċi msejħa serotip 1 u serotip 2.

in absssi, the types of infections treated were confined to cellulitis/erysipelas or major cutaneous abscesses, and wound infections only.
f’absssi, it-tipi ta’ infezzjonijiet ikkurati kienu ristretti għal ċellulite/irsipli jew axxessi kutanji maġġuri, u infezzjonijiet fil-feriti biss.

for mixed use the onset and duration of immunity of the parvovirus component and the onset of immunity of the erysipelas component have been demonstrated to be equivalent to those determined for eryseng parvo when used alone.
għall-użu mħallat il-bidla u t-tul tal-immunità tal-komponenti parvovirus u l-bidla tal-immunità tal- komponent erysipelas intwera li huma ekwivalenti għal dawk maħsuba għal eryseng parvo meta użati waħedhom.

for the active immunisation of male and female pigs to reduce clinical signs (skin lesions and fever) of swine erysipelas caused by erysipelothrix rhusiopathiae, serotype 1 and serotype 2.
għat-tilqim attiv tal-majjali rġiel u nisa sabiex jitnaqqsu s-sinjali kliniċi (leżjonijiet tal-ġilda u deni) ta’ erisipelas tal-majjali kkawżata minn erysipelothrix rhusiopathiae, serotip 1 and serotip 2.

the referral deals with the issue that in the opinion of france equivalence between the reference vaccine batch for the erysipelas batch potency test validated in the original dossier and the new reference vaccine batches was not shown for these 2 batches and that consequently the cvmp needed to consider whether to vary, withdraw or suspend the marketing authorisation.
ir- referenza tindirizza l- kwistjoni li fl- opinjoni ta ’ franza, l- ekwivalenza bejn il- lott tal- vaċċin ta ’ referenza għat- test tal- qawwa tal- lott ta ’ erysipelas ivvalidat fid- dossier oriġinali u l- lottijiet tal- vaċċin ta ’ referenza l- ġodda ma ntwerietx għal dawn iż- żewġ lottijiet u li konsegwentement is- cvmp kien jeħtieġ jikkunsidra jekk għandux ivarja, jirtira jew jissospendi l- awtorizzazzjoni għat- tqegħid fis- suq.

21 skin lesions induced by cetuximab may predispose patients to superinfections (e. g. with s. aureus), which may lead to subsequent complications, e. g. cellulitis, erysipelas, or, potentially with fatal outcome, staphylococcal scalded skin syndrome or sepsis.
leżjonijiet fil- ġilda kkaġunati minn cetuximab jistgħu jippredisponu lill- pazjenti għal superinfezzjonijiet (eż. b’ s. aureus), li jistgħu jinfexxu f’ kumplikazzjonijiet oħra, eż. ċellulite, erysipelas, jew, potenzjalment b’ riżultat fatali, is- sindrome ta ’ ġilda mismuta bi staphylococcus jew b’ xi mikrobu ieħor.